HYPERTAM

"Evaluation of the synergy between tamoxifen chemotherapy and hypericin photodynamic action, following mitochondrial complex III photo-inhibition: Towards a combinatorial anticancer treatment modality"

Coordinatore	OSLO UNIVERSITETSSYKEHUS HF    more  Organization address address: FORSKNINGSVEIEN 2B city: OSLO postcode: 373 contact info Titolo: Prof. Nome: Kristian Cognome: Berg Email: send email Telefono: 4722781479 Fax: 4722781495
Nazionalità Coordinatore	Norway [NO]
Totale costo	301˙250 €
EC contributo	301˙250 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IEF
Funding Scheme	MC-IEF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-06-07   -   2015-07-22

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	OSLO UNIVERSITETSSYKEHUS HF  Organization address address: FORSKNINGSVEIEN 2B city: OSLO postcode: 373 contact info Titolo: Prof. Nome: Kristian Cognome: Berg Email: send email Telefono: 4722781479 Fax: 4722781495	NO (OSLO)	coordinator	301˙250.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'In the present Marie Curie Intra European Fellowship application, HYPERTAM, we propose to combine our recent complementary findings in two separate anticancer therapeutic modalities, namely, photodynamic therapy of cancer (PDT) with hypericin or other phototoxins and tamoxifen chemotherapy, fusing them in one combinatorial treatment predicted to demonstrate enhanced antitumoural potency through synergy of tamoxifen action with hypericin photo-inactivation (inhibition) of mitochondrial complex III quinoloxidizing centre. The main points to be addressed by HYPERTAM are summarized as follows: (i) Revisit and expound the tamoxifen - complex III inhibitor cytotoxic interplay findings. (ii) Explore the predicted hypericin PDT-tamoxifen synergistic action in selected cell models. (iii) Evaluate other photosensitizers with high clinical relevance. (iv) Investigate the cell death pathways implicated in the most striking in-vitro results (v) translate the most important in-vitro combinatorial treatment results to corresponding animal models for a pilot preclinical assessment. The fellowship is expected give the applicant a unique opportunity to acquire key skills and knowledge like: (i) competences in molecular biology including evaluation of cell death mechanisms and pathways (ii) competencies in the use of novel lab techniques and instrumentation (iii) certified competencies in animal tumour models. (iv) competencies in management, administration and entrepreneurial activities. The possibility to run HYPERTAM represents a unique opportunity for the applicant to perfect his professional profile, and at a very critical juncture, steer his career towards independent research. The expected result of the proposed project, a cross-disciplinary bimodal anticancer treatment modality with high potency, is of high socioeconomic value, and is expected to greatly contribute to European excellence and competitiveness.'